Exelixis Return on Equity

Exelixis (EX9.DE) currently reports a ROE of 33.42%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Exelixis's ROE history and peer comparisons.

Exelixis's ROE of 33.42% is higher than the Healthcare sector average of -75.59%. That is roughly 144.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Exelixis's current 33.42% should be judged against Healthcare norms (sector average: -75.59%) and against EX9.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 33.42%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Exelixis, and consider following EX9.DE for alerts when major investors trade the stock.

Exelixis is classified in the Healthcare sector. On ROE, it currently shows 33.42% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EX9.DE with unrelated industries.